InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results
FDA has granted the drug priority review status due to the unmet medical need it addresses.
FDA has granted the drug priority review status due to the unmet medical need it addresses.